The role of tissue renin-angiotensin system on cardiovascular and renal hypertrophy/hyperplasia

点击翻译按钮获取中文摘要

1. We assessed the cardio- and reno-protective effects of three kinds of long-acting antihypertensive drugs in rats with chronic renal failure (CRF){an angiotensin II receptor antagonist, an ACE inhibitor, and a calcium channel blocker}. The results indicate that these long-acting antihypertensive drugs equally have the potency to protect heart and kidney in rats with CRF.2. We assessed the potential of the kallikrein-kinin system in mediating the cardio-and reno-protective effects of ACE inhibitors in rats with chronic renal failure (CRF) using ACE inhibitors, a kinin antagonist and an AII receptor antagonist. These results indicate that the kallikrein-kinin system might not play a major role in the cardio-and reno-protective effects of ACE inhibitors in rats with CRF.3. We assessed the cardiac and the renal benefit of an angiotensin II receptor antagonist, losartan, in diabetic rats with renal impairment. The results indicate the hypertension could accelerate diabetic renal impairment and that losartan has antihypertensive and renoprotective effects in this rat model. The difference in potency between losartan treatment and captopril treatment to attenuate the increase in heart weight : body weight ratio might partly explain the existence in the heart of abgiotensin-forming pathways, which are not dependent on angiotensin converting enzyme.4. The effects of prolonged chlorothiazide (CTZ) treatment of left ventricular failure on cardiac hypertrophy, circulating vasoactive hormones and total exchangeable body sodium (NaE) were examined in rats with chronic myocardial infarction induced by left coronary artery ligation. CTZ does not cause regression of cardiac hypertrophy in rats with left ventricular failure and activates the renin angiotensin system.